key: cord-0822943-5tdwgxty
authors: Mondi, A.; Cimini, E.; Colavita, F.; Cicalini, S.; Pinnetti, C.; Matusali, G.; Casetti, R.; Maeurer, M.; Vergori, A.; Mazzotta, V.; Gagliardini, R.; De Zottis, F.; Schininà, V.; Girardi, E.; Puro, V.; Ippolito, G; Vaia, F.; Capobianchi, M.R.; Castilletti, C.; Agrati, C.; Antinori, A.
title: COVID‐19 in people living with HIV: clinical implications of dynamics of immune response to SARS‐CoV‐2
date: 2020-09-25
journal: J Med Virol
DOI: 10.1002/jmv.26556
sha: 60631e94ef8962994f723d0bc72f530eed143576
doc_id: 822943
cord_uid: 5tdwgxty

BACKGROUND: Little evidence on COVID‐19 in people living with HIV (PLWH) is currently available. MATERIAL AND METHODS: We reported clinical and viro‐immunological data of all HIV‐positive patients admitted to our centre with COVID‐19 from March 1 to May 12(,)2020. RESULTS: Overall, five patients were included: all were virologically‐suppressed on antiretroviral therapy and CD4+ count was >350 cell/mm(3) in all but two patients. Although all patients had evidence of pneumonia on admission, only one developed respiratory failure. SARS‐CoV‐2‐RNA was never detected from nasopharyngeal swabs in two patients, whereas, in the others, viral clearance occurred within a maximum of 43 days. IgG production was elicited in all patients and neutralizing antibodies in all but one patient. Specific‐T‐cell response developed in all patients but was stronger in those with more severe presentation. Similarly, the highest level of pro‐inflammatory cytokines was found in the only patient experiencing respiratory failure. Despite a mild presentation, patients with more pronounced immunosuppression showed high degrees of both cytokines production and immune‐activation. CONCLUSIONS: Our study did not find an increased risk and severity of COVID‐19 in PLWH. Adaptative cellular immune response to SARS‐CoV‐2 appeared to correlate to disease severity. The mild clinical picture showed in advanced HIV patients, despite a significant T‐cell activation and inflammatory profile, suggests a potential role of HIV‐driven immunological dysregulation in avoiding immune‐pathogenetic processes. However, other possible explanations, as a protective role of certain antiretroviral drugs, should be considered. Further larger studies are needed to better clarify the impact of HIV infection on COVID‐19. This article is protected by copyright. All rights reserved.

Currently, the limited available data on COVID-19 in people living with HIV (PLHW) do not clearly suggest a higher infection rate or a more severe course of SARS-CoV-2 infection compared to the general population [1] [2] [3] [4] [5] , as it might be expected given the immunosuppression and the high prevalence of classic risk factors for severe COVID-19 manifestations (older age and comorbidities) in this population. Particularly, the role of HIV-related immunodepression on COVID-19 course is still a matter of debate. Indeed, a low CD4 T-cell count has already been associated with an increased risk of mortality in several infections. However, in light of the central role of the host immune response in the pathogenesis of severe manifestations of SARS-CoV-2 infection, it has been postulated that a defective cellular immunity could paradoxically prevent from COVID-19 complications [6] . Despite this uncertainty and the growing evidence on immune response to SARS-CoV-2 infection in the general population, data on immunological dynamics in HIV-positive subjects are still lacking.

Here, we describe the experience of an Italian reference HIV/AIDS centre in one of the National referral hospitals for COVID-19 with particular insights into immunologic response to SARS-CoV-2 infection.

We included all subjects with a diagnosis of HIV infection and a laboratory-confirmed SARS-CoV-2 infection admitted to the National Institute for Infectious Diseases L.

Spallanzani IRCCS in Rome between March 1 and May 12, 2020. Demographic and clinical data were collected through review of medical records. Laboratory and radiologic assessments during hospitalization and after discharge were performed according to treating physician judgment and hospital internal protocols. All patients gave informed consent for using their data for research purpose.

A confirmed case of COVID-19 was defined by a positive real-time reverse-transcription PCR (RT-PCR) assay for SARS-CoV-2 on nasopharyngeal swab and/or a positive serology for SARS-CoV-2 (positivity of Immunoglobulin (Ig) G or M or A).

Severe disease was defined as clinical signs of pneumonia plus one of the following: respiratory rate greater than 30 breaths per min, severe respiratory distress or oxygen saturation less than 90% on room air [7] . Viral clearance was defined as two consecutive negative RT-PCR for SARS-CoV-2 on nasopharyngeal swab.

All included patients underwent to follow-up nasopharyngeal swabs to assess the viral clearance. RT-PCR targeting the E and RdRp viral genes was used to assess the presence of SARS-CoV-2 RNA [8] .

All patients included in the study underwent to a complete immunological assessment.

Humoral immunity (SARS-CoV-2 specific Immunoglobulins) was evaluated by quantifying IgA, IgG and IgM by Immunofluorescence, and by dosing the neutralizing antibodies (nAb) in BSL-3 facility.

Detection of specific Ig for SARS-CoV-2 was performed using indirect immunofluorescence assay on slides prepared in-house with Vero E6 cells infected with Accepted Article SARS-CoV-2 isolate, as described elsewhere [9] . Each sample was tested using 1:20 screening dilution; positively screened samples were titrated by limiting dilution. FITCconjugated rabbit anti-human IgM, IgA and IgG antibodies (Euroimmun, Germany) were used as secondary antibody and Evans Blue as cell counterstain.

For microneutralization test, patients' sera were heat-inactivated, diluted 1:10 in serumfree medium, and titrated in duplicate in two-fold dilutions. Equal volumes of 100 TCID50/well SARS-CoV-2 (2019-nCoV/Italy-INMI) and serum dilutions were mixed and incubated at 37°C for 30 minutes. Virus-serum mixtures were added to sub-confluent Vero E6 cells and incubated at 37 °C and 5% CO2 for two days. Neutralizing antibody titers were calculated as the last serum dilution not presenting cytopathic effect.

Innate immunity was evaluated in three of five patients (patients 1,2 and 4) for whom follow-up whole blood samples were available. Gating strategy was used to identify natural killer (NK) cell population. NK cells were gated as CD45+CD3-CD56+ cells.

Additionally, the expression of activatory (NKG2C) and inhibitory (NKG2A) receptors was longitudinally quantified by flow cytometry at three different time points (approximately at one, two and three weeks from symptom onset or hospital admission in patient 1 and patient 4, respectively and at 7, 11 and 14 days from symptoms onset in patient 2). Moreover, the content of granzyme and perforin in NK cells was quantified by flow cytometry.

Specific cellular immune response was evaluated by quantifying SARS-CoV-2 specific Tcells (specific for Spike and Nucleocapside proteins) by Elispot assay. As positive control (the evaluation of the immunocompetence) peripheral blood mononuclear cells (PBMCs) were stimulated with phytohemagglutinin (PHA) (data not shown) and with cytomegalovirus (CMV)-specific antigen. As negative control (spontaneous interferon (IFN)-γ release), PBMCs were maintained in culture medium without specific stimulation.

The inflammatory profile in plasma samples was quantified by enzyme-linked immunosorbent assay (ELISA) for interleukin (IL)-6, IL-8 and IL-1β.

Over the observation period, 604 subjects with confirmed SARS-CoV-2 infection were admitted to our centre. Among them, five HIV-positive patients were found (crude prevalence 0.8%). This article is protected by copyright. All rights reserved.

Main demographic and clinical characteristics and outcomes are summarized in Table 1 .

Briefly, four patients were male with an age ranging between 46 and 61 years and one was Concerning antiviral therapy, four patients received hydroxychloroquine for 10 days without changing baseline ART whereas one patient underwent to a transitional change of initial ART to a boosted protease-inhibitor (PI/b)-based regimen for 14 days. During hospitalization, only one patient (patient 1) developed acute respiratory failure that successfully responded to immunomodulatory therapy with steroids and intravenous tocilizumab, an IL-6 inhibitor. Only two patients (patients 1 and 2) temporarily required oxygen supplement with Venturi mask and both weaned from oxygen before the discharge. Three patients showed improvement or resolution of the lung involvement at the followup HRCT scan whereas in the other two (patients 3 and 4) no significant changes were observed. All patients were discharged within 20 days. Two of them were discharged with positive RT-PCR for SARS-CoV-2 on nasopharyngeal swab and viral clearance was assessed by territorial health service.

In two of five patients (patients 1 and 4), SARS-CoV-2 RNA was never detected in nasopharyngeal swabs and COVID-19 diagnosis was made by means of positive serology. This article is protected by copyright. All rights reserved.

In the other three patients, viral clearance occurred within a maximum time of 43 days from illness onset or hospital admission.

whereas IgA were positive in four patients and IgM just in one patient. The range between symptoms onset (or hospital admission for asymptomatic patients) and serology collection varied widely among patients (Table 1 ). All but one patient (patient 4) displayed nAb production. Patients 1 and 4 underwent to a second serology determination after 7 and 32 days respectively which showed a four-fold increase of IgG and IgA and a two-fold increase of IgM titers in the former and no change in the Ig titers in the latter.

A greater T cell response against SARS-CoV-2 antigens was observed in patients with a more severe COVID-19 presentation and/or with a more prolonged viral shedding (patients 1 and 2) whereas was less pronounced in the other ones (Fig 1a) . Particularly, patient 4, who was the most severely immunocompromised subject, lacked of both specific T cell response and nAb production. Of note, this patient showed a significant increase of the cellular immune response after 32 days from admission (Fig 1b) whereas the production on nAb persistently lacked.

With regard to the innate immune response, as shown in figures 1c and 1d, NK cells from patient 4 expressed higher level of activatory receptors (NKG2C) than the other two patients. Additionally, in the same patient a parallel lower expression of inhibitory receptors (NKG2A) compared to the others was observed, suggesting the presence of highly engaged/activated NK cells. These cells were activated (90% expressed CD38) and enriched in perforin/granzyme cycotoxic molecules (76,4% were granzyme positive and perforine positive).

As expected, the proportion of CD4 and CD8 T lymphocytes expressing activation markers (CD38) was high in patients with advanced HIV-related immunosuppression (patients 3 and 4). On the contrary, a low degree of immune-activation was observed in the subjects with a better control of HIV infection regardless of COVID-19 severity (Fig 1e) . Finally, the highest levels of pro-inflammatory cytokines were observed in patient 1 showing the most severe COVID-19 presentation. A significant production of IL-6 and IL-8 was also observed in the two patients with less controlled HIV-infection (patients 3 and 4), albeit to a lesser extent than patient 1 (Fig 1f) . This article is protected by copyright. All rights reserved.

This study describes clinical characteristics and outcomes of HIV-positive patients admitted with a COVID-19 diagnosis to our hospital, a reference national HIV/AIDS centre, regularly following approximately 7,000 outpatients, and one of the Italian reference hospitals for the COVID-19 pandemic.

Our findings did not seem to support the hypothesis of an increased risk and a greater severity of COVID-19 in PLWH. Indeed, consistently with previous data [1, 5, 10] , in this study, HIV-positive subjects accounted for less than 1% of patients admitted to our hospital with a diagnosis of SARS-CoV2-infection. Unfortunately, due to the lack of updated information about clinical and serological data of our HIV-positive outpatient cohort, we could not draw any conclusion about COVID-19 incidence rate in our centre. However, recent results from other cohorts reported very low rates of SARS-CoV-2 infection in PLWH, approximately 1% or less [2, 4, 11] .

Concerning clinical severity, in our series, although all patients had evidence of lung involvement on admission with radiological patterns similar to those described for the HIV-negative population [12] , none of them had a critical course of COVID-19 and all were discharged from hospital within twenty days. The only subject experiencing a severe course of infection with acute respiratory failure successfully responded to immunotherapy. These findings are in line with recent reports showing that HIV infection did not seem to impact on clinical severity and mortality of COVID-19 [1] [2] [3] [4] [5] 10] .

Despite these optimistic findings, the lack of higher risk for severe COVID-19 in PLWH has been recently questioned by several studies reporting worse outcomes in HIV-positive subjects compared to the general population, and particularly in frailer subgroups as elderly [4, 13, 14] , patients with underlying comorbidities [14, 15] , more severely immunosuppressed patients [13, 14] and black people [16] . Indeed, older age and comorbidities, already identified as risk factors for severe disease in the general population, have been clearly related to a greater risk of both acquiring and having a severe clinical course of COVID-19 also in PLWH [4, [13] [14] [15] . Notably, several studies have reported a significant correlation between age and disease severity [14] , with a greater risk of morbidity and mortality for COVID-19

in the older age strata of the HIV-positive population compared to the general population [4, 13] . The premature ageing and the premature burden of age-related diseases due to the chronic immune-activation, which characterizes HIV-positive subjects, might probably This article is protected by copyright. All rights reserved.

explain these results [17] . Of note, in this study, the only subject experiencing a severe course of COVID-19 was the oldest among our patients.

Conversely the association between the classic HIV-related parameters of immunosuppression and the severity of disease appeared to be less defined. Indeed, in two large cohort studies on HIV-positive patients with SARS-CoV-2 infection, although subjects with more severe course of infection had lower CD4 cell count, a significant correlation between immunological status and adverse outcomes was not found [12, 13] .

Additionally, in a recent case series describing four SARS-CoV2/HIV co-infected patients, despite a worse evolution of COVID-19 in patients with advanced HIV stage, a direct association between immunosuppression and disease course could not be assumed [18] . In fact, the overlapping of opportunistic infections and the lack of antiretroviral therapy and virologic control in severely immunocompromised patients might partially account for the worse evolution.

In this study, consistently to how previously reported in both SARS-CoV-2 infection [1] [2] [3] [4] [5] and previous coronavirus diseases [19, 20] , we did not find an association between the severity of HIV-related immunodeficiency and a worse clinical course of COVID-19.

Indeed, patient 1, the only experiencing a severe course of SARS-CoV-2 infection, was a Caucasian man with an optimal immunological profile (baseline CD4 count: 438 cell/mm 3 ). Conversely, the two asymptomatic patients (patients 3 and 4) were the more severely immunocompromised. Of note, one of them was black and had several comorbidities.

As already suggested [2, 6] , a possible explanation is that a highly defective cellular immunity in HIV-positive patients may reduce the immune-mediated pathogenesis of COVID-19. Indeed, in seronegative subjects, the severity of COVID-19 was associated to a huge inflammatory response, to a stronger T cells activation and to a dramatic lymphopenia [21] [22] [23] . Accordingly, patient 1 showed the most significant pro-inflammatory response. Conversely, the significant immune-activation and inflammatory profile observed in the most severely immunocompromised patients did not seem to worsen the course of COVID-19. These data confirm a role of inflammation in COVID-19 severity in PLWH and suggest that the low and impaired immune reactivity in patients with advanced HIV disease may possibly play a role in reducing the COVID-19 evolution towards This article is protected by copyright. All rights reserved.

severity. However, further well-design studies with larger sample size are mandatory to confirm this hypothesis and to identify immunological players of COVID-19 severity.

The degree of immunosuppression is not the only potential explanation for the different course of SARS-CoV-2 infection in our cohort. To this regard, a possible impact of the different antiretroviral regimens should be considered. Indeed, given the effect of some antiretroviral drugs on SARS-CoV-2 life-cycle, a potential role of chronic ART in preventing incidence and complications of COVID-19 has been postulated [24] . Particularly the boosted protease inhibitors lopinavir/ritonavir and DRV/b and the nucleoside reverse transcriptase inhibitor (NRTI) tenofovir have been proposed as potentially protective drugs for SARS-CoV-2, based on contradictory results of randomized clinical trials and observational studies for lopinavir/ritonavir and in-vitro activity or molecular docking studies for the others [25] . It is worth nothing, that in our cohort, patients on tenofovir-based regimens (patients 3,4 and 5) seemed to have milder clinical manifestations compared to patients on DRV/b-based dual ART who experienced severe disease course (patient 1) or prolonged viral shedding (patient 2). Our finding is consistent with a recent large cohort study reporting a lower risk for both acquiring and having complications of SARS-CoV-2 infection in patients assuming tenofovir disoproxil fumarate/emtricitabine (TDF) [4] but contrasts with most reports which did not find any significant association between the use of either ART or specific antiretroviral drugs and clinical outcomes. The results of an ongoing trial on TDF as pre-exposure prophylaxis [26] and of larger studies on HIV-positive cohorts may better clarify this aspect.

To better understand the potential role of HIV-driven immunological dysregulation on SARS-CoV-2 specific response, we evaluated both humoral and cellular (innate and adaptative) arms of the immune system. Patients with moderate/severe disease showed a higher T cell response to the viral antigens, suggesting a stronger and prolonged host/pathogen interaction able to boost SARS-CoV-specific T cell clones. In contrast, the cellular immune response was low/absent in asymptomatic patients suggesting a rapid clearance of virus mainly induced by innate immune cells. This hypothesis is supported by the finding of a significantly higher number of activated NK cells in patient 4 compared to patients with more severe disease evolution (patient 1) or longer shedding (patient 2). The 

COVID-19, a hyperexpression of inhibitory receptors (NKG2A) compared to mild cases, potentially responsible for the functional exhaustion of these cytotoxic immune cells and disease progression [23] . Another recent report showed an association between the development of critical illness and the presence of NK2GC receptor deletion/genetic variants of its ligand (HLA-E) characterized by lower surface expression [27] . Additionally, on the basis these findings, some authors have proposed the use of anti-NKG2A monoclonal antibody monalizumab as a weapon for severe COVID-19 cases [28] .

According to these reports, in our study, the activatory profile of NK cells, with high level of NKG2C and low level of NKG2C, expressed by patient 4 might have contributed to the rapid viral clearance and to the lack of disease progression.

Concerning humoral immunity, all patients showed a good specific antibody response and, interestingly, in patient 4, the low and delayed T cell response was associated to a lack of neutralizing antibody production. The significance of low T cells response and absence of nAb on the long-lasting protection represent a critical issue to be addressed in both HIVpositive and negative subjects.

Finally, regarding viral kinetic, a recent study reported in PLWH a median time to viral clearance of 18 days with a higher risk of prolonged shedding in individuals with more severe course, similarly to how described in the general population [29] , and in subjects with a low CD4 nadir [13] . In our cohort, viral shedding was not evaluable for three patients (two in whom viral RNA was never detected on nasopharyngeal swabs and one, asymptomatic, in whom time of illness onset was not defined). The other two patients had prolonged viral shedding (more than 20 days) which was not associated to a severe clinical course or a history of a serious immunodeficiency.

Our study has several limitations. First, the exiguous sample size that, making difficult to distinguish real effects from random variations, prevents us to draw any definitive conclusions. Second, the observational and uncontrolled nature of the study which do not allow us to completely rule out residual or unmeasured confounders. Furthermore, the retrospective collection of medical records that may have introduced bias due to the potential inaccurate reporting of data and to missing data. Finally, the limited duration of follow-up which prevented us to follow-up the evolution of immune response. However, this study has also the strength to provide, for the first time to the best of our knowledge,

insights into the dynamics of immune response to SARS-CoV-2 infection in PLWH and the potential clinical significance of these pathogenic features.

In conclusion, our findings seem to confirm that HIV-positive patients are not at increased 

Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort Study

Outcomes among HIVpositive patients hospitalized with COVID-19

Could HIV infection alter the clinical course of SARS-CoV-2 infection? When less is better

Clinical management of COVID-19

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Inflammatory and Humoral Immune Response during Ebola Virus Infection in Survivor and Fatal Cases Occurred in Sierra Leone during the 2014-2016 Outbreak in West Africa. Viruses

UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

A survey for COVID-19 among HIV/AIDS patients in two districts of Wuhan

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort

SARS-CoV-2 infection in persons living with HIV: a single center prospective cohort

Characteristics and outcomes of COVID-19 in patients with HIV: a multi-center research network study

Hospitalized patients with COVID-19 and HIV: a case series

Premature Aging and Premature Age-Related Comorbidities in HIV-Infected Patients: Facts and Hypotheses

Clinical features and outcomes of four HIV patients with COVID-19 in Wuhan

Successful recovery of MERS CoV pneumonia in a patient with acquired immunodeficiency syndrome: a case report

Coronavirus infection in an AIDS patient

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

COVID-19 and AIDS: Outcomes from the coexistence of two global pandemics and the importance of chronic antiretroviral therapy

Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment

Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel (EPICOS)

NK cell receptor NKG2C deletion and HA-E variants are risk factors for severe COVID-19